During the last session, Coherus BioSciences Inc. (NASDAQ:CHRS)’s traded shares were 2.3 million, with the beta value of the company hitting 0.97. At the end of the trading day, the stock’s price was $4.34, reflecting an intraday loss of -4.82% or -$0.22. The 52-week high for the CHRS share is $14.11, that puts it down -225.12 from that peak though still a striking -0.46% loss since the share price plummeted to a 52-week low of $4.36. The company’s market capitalization is $347.29M, and the average intraday trading volume over the past 10 days was 3.69 million shares, and the average trade volume was 1.56 million shares over the past three months.
Coherus BioSciences Inc. (CHRS) received a consensus recommendation of an Overweight from analysts. That translates to a mean rating of 2.20. CHRS has a Sell rating from 0 analyst(s) out of 9 analysts who have looked at this stock. 2 analyst(s) recommend to Hold the stock while 1 suggest Overweight, and 6 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.62.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
Sponsored
Coherus BioSciences Inc. (NASDAQ:CHRS) trade information
Coherus BioSciences Inc. (CHRS) registered a -4.82% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -4.82% in intraday trading to $4.34 this Wednesday, 05/24/23, hitting a weekly high. The stock’s 5-day price performance is -13.55%, and it has moved by -44.22% in 30 days. Based on these gigs, the overall price performance for the year is -45.68%. The short interest in Coherus BioSciences Inc. (NASDAQ:CHRS) is 10.54 million shares and it means that shorts have 12.09 day(s) to cover.
The consensus price target of analysts on Wall Street is $15.00, which implies an increase of 71.07% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $8.00 and $24.00 respectively. As a result, CHRS is trading at a discount of -453.0% off the target high and -84.33% off the low.
Coherus BioSciences Inc. (CHRS) estimates and forecasts
Statistics show that Coherus BioSciences Inc. has outperformed its competitors in share price, compared to the industry in which it operates. Coherus BioSciences Inc. (CHRS) shares have gone down -34.24% during the last six months, with a year-to-date growth rate more than the industry average at 47.35% against 11.40. Yet analysts are ramping up their growth forecast for the fiscal year 2023. Revenue is predicted to shrink -31.90% this quarter and then jump 66.70% in the quarter after that. In the rating firms’ projections, revenue will increase 41.80% compared to the previous financial year.
Revenue for the current quarter is expected to be $54.87 million as predicted by 9 analyst(s). Meanwhile, a consensus of 9 analyst(s) estimates revenue growth to $84.55 million by the end of Sep 2023. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $60.15 million and $56.91 million respectively. In this case, analysts expect current quarter sales to shrink by -8.80% and then jump by 48.60% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 3.50%. While earnings are projected to return 1.20% in 2023.
CHRS Dividends
Coherus BioSciences Inc. is due to release its next quarterly earnings in June. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Coherus BioSciences Inc. (NASDAQ:CHRS)’s Major holders
Coherus BioSciences Inc. insiders own 1.88% of total outstanding shares while institutional holders control 103.23%, with the float percentage being 105.21%. Blackrock Inc. is the largest shareholder of the company, while 257 institutions own stock in it. As of Mar 30, 2023, the company held over 14.4 million shares (or 17.87% of all shares), a total value of $98.48 million in shares.
The next largest institutional holding, with 7.38 million shares, is of Temasek Holdings (Private) Limited’s that is approximately 9.16% of outstanding shares. At the market price on Mar 30, 2023, these shares were valued at $50.49 million.
Also, the Mutual Funds coming in first place with the largest holdings of Coherus BioSciences Inc. (CHRS) shares are iShares Core S&P Smallcap ETF and SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF. Data provided on Feb 27, 2023 indicates that iShares Core S&P Smallcap ETF owns about 4.87 million shares. This amounts to just over 6.04 percent of the company’s overall shares, with a $32.96 million market value. The same data shows that the other fund manager holds slightly less at 3.98 million, or about 4.95% of the stock, which is worth about $26.97 million.
